Lesley A Houghton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957629/publications.pdf

Version: 2024-02-01

123 11,377 47 papers citations h-index

125 125 125 7715
all docs docs citations times ranked citing authors

105

g-index

#	Article	IF	CITATIONS
1	Functional Bowel Disorders. Gastroenterology, 2006, 130, 1480-1491.	0.6	4,197
2	Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology, 2006, 130, 34-43.	0.6	304
3	Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DNâ€173â€f010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2009, 29, 104-114.	1.9	289
4	Changes of the human gut microbiome induced by a fermented milk product. Scientific Reports, 2014, 4, 6328.	1.6	217
5	Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology, 1988, 94, 1285-1291.	0.6	214
6	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 2021, 70, 1214-1240.	6.1	212
7	The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut, 2002, 50, 471-474.	6.1	200
8	Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. American Journal of Gastroenterology, 2002, 97, 954-961.	0.2	195
9	Acoustic Coughâ€"Reflux Associations in Chronic Cough: Potential Triggers and Mechanisms. Gastroenterology, 2010, 139, 754-762.	0.6	177
10	Effect of a second-generation $\hat{A}2\hat{A}$ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut, 2007, 56, 1218-1225.	6.1	174
11	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Human Molecular Genetics, 2008, 17, 2967-2977.	1.4	173
12	Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 437-447.	1.4	171
13	Motor activity of the gastric antrum, pylorus, and duodenum under fasted conditions and after a liquid meal. Gastroenterology, 1988, 94, 1276-1284.	0.6	162
14	Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut, 2003, 52, 663-670.	6.1	158
15	Role of the proximal and distal stomach in mixed solid and liquid meal emptying Gut, 1991, 32, 615-619.	6.1	153
16	Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Alimentary Pharmacology and Therapeutics, 2006, 24, 183-205.	1.9	141
17	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut, 2020, 69, 1441-1451.	6.1	137
18	Physiological effects of emotion: assessment via hypnosis. Lancet, The, 1992, 340, 69-72.	6.3	134

#	Article	IF	CITATIONS
19	Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 17, 635-642.	1.9	130
20	Syuptomatology, quality of life and economic features of irritable bowel syndromeâ€"the effect of hypnotherapy. Alimentary Pharmacology and Therapeutics, 1996, 10, 91-95.	1.9	126
21	Relationship of Abdominal Bloating to Distention in Irritable Bowel Syndrome and Effect of Bowel Habit. Gastroenterology, 2006, 131, 1003-1010.	0.6	124
22	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut, 2020, 69, 74-82.	6.1	122
23	Efficacy of Secretagogues in Patients With Irritable BowelÂSyndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology, 2018, 155, 1753-1763.	0.6	119
24	Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Alimentary Pharmacology and Therapeutics, 2000, 14, 775-782.	1.9	118
25	Effect of meal temperature on gastric emptying of liquids in man Gut, 1988, 29, 302-305.	6.1	106
26	Rome III Functional Constipation and Irritable Bowel Syndrome With Constipation Are Similar Disorders Within a Spectrum of Sensitization, Regulated by Serotonin. Gastroenterology, 2013, 145, 749-757.	0.6	106
27	Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation. Gastroenterology, 2016, 150, 1292-1304.e2.	0.6	103
28	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	6.1	97
29	Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers Gut, 1990, 31, 1226-1229.	6.1	96
30	Bloating and Distention in Irritable Bowel Syndrome: The Role of Visceral Sensation. Gastroenterology, 2008, 134, 1882-1889.	0.6	96
31	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	9.4	96
32	Physiology of Gastric Emptying and Pathophysiology of Gastroparesis. Gastroenterology Clinics of North America, 1989, 18, 359-373.	1.0	89
33	Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. American Journal of Physiology - Renal Physiology, 1988, 254, G671-G679.	1.6	86
34	Bloating and Distension in Irritable Bowel Syndrome: The Role of Gastrointestinal Transit. American Journal of Gastroenterology, 2009, 104, 1998-2004.	0.2	85
35	Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 445-460.	8.2	82
36	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. Clinical Gastroenterology and Hepatology, 2020, 18, 392-398.e2.	2.4	78

#	Article	ΙF	Citations
37	Age, Gender, and Women's Health and the Patient. Gastroenterology, 2016, 150, 1332-1343.e4.	0.6	77
38	Chronic Cough. Chest, 2012, 142, 958-964.	0.4	75
39	Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterology and Motility, 2005, 17, 810-820.	1.6	72
40	Visceral sensation and emotion: a study using hypnosis. Gut, 2002, 51, 701-704.	6.1	67
41	Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterology and Motility, 2005, 17, 500-511.	1.6	66
42	Is chest pain after sumatriptan oesophageal in origin?. Lancet, The, 1994, 344, 985-986.	6.3	65
43	Diagnostic Criteria for Irritable Bowel Syndrome: Utility and Applicability in Clinical Practice. Digestion, 2004, 70, 210-213.	1.2	64
44	Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut, 2001, 48, 216-220.	6.1	61
45	Effect of sumatriptan, a new selective 5HT ₁ â€like agonist, on liquid gastric emptying in man. Alimentary Pharmacology and Therapeutics, 1992, 6, 685-691.	1.9	61
46	Does the menstrual cycle affect anorectal physiology?. Digestive Diseases and Sciences, 1994, 39, 2607-2611.	1.1	57
47	British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut, 2022, 71, 1697-1723.	6.1	54
48	Impaired Esophageal Motility and Clearance Post-Lung Transplant: Risk For Chronic Allograft Failure. Clinical and Translational Gastroenterology, 2017, 8, e102.	1.3	51
49	Do male sex hormones protect from irritable bowel syndrome?. American Journal of Gastroenterology, 2000, 95, 2296-2300.	0.2	50
50	Alpha 2 Delta $(\hat{l}\pm2\hat{l})$ Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. Frontiers in Pharmacology, 2011, 2, 28.	1.6	49
51	The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexes. Cough, 2013, 9, 12.	2.7	47
52	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Scientific Reports, 2017, 7, 14680.	1.6	46
53	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. American Journal of Gastroenterology, 2021, 116, 372-381.	0.2	43
54	5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. European Journal of Gastroenterology and Hepatology, 2010, 22, 856-861.	0.8	42

#	Article	IF	CITATIONS
55	Effect of the NK3receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterology and Motility, 2007, 19, 732-743.	1.6	41
56	5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Alimentary Pharmacology and Therapeutics, 1999, 13, 1437-1444.	1.9	40
57	A Novel Approach to Studying the Relationship Between Subjective and Objective Measures of Cough. Chest, 2011, 139, 569-575.	0.4	40
58	Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterology and Motility, 2007, 19, 724-731.	1.6	38
59	Phenotyping of subjects for large scale studies on patients with <scp>IBS</scp> . Neurogastroenterology and Motility, 2016, 28, 1134-1147.	1.6	36
60	Weak peristalsis with large breaks in chronic cough: association with poor esophageal clearance. Neurogastroenterology and Motility, 2015, 27, 431-442.	1.6	35
61	A metaâ€analysis of immunogenetic Case–Control Association Studies in irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 717-727.	1.6	35
62	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 362-371.	0.2	34
63	Physiology of gastric emptying and pathophysiology of gastroparesis. Gastroenterology Clinics of North America, 1989, 18, 359-73.	1.0	33
64	Zamifenacin (UK-76, 654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 1997, 11, 561-568.	1.9	30
65	Anxietyâ€related factors associated with symptom severity in irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13872.	1.6	30
66	Disturbed gastroduodenal motility in patients with active and healed duodenal ulceration. Gastroenterology, 1991, 100, 892-900.	0.6	29
67	A comparative study of the effect of cimetidine and ranitidine on the rate of gastric emptying of liquid and solid test meals in man. Alimentary Pharmacology and Therapeutics, 1987, 1, 401-408.	1.9	29
68	Measurement of serotonin in platelet depleted plasma by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2163-2167.	1.2	29
69	New Developments in Reflux-Associated Cough. Lung, 2010, 188, 81-86.	1.4	29
70	5â€hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. Alimentary Pharmacology and Therapeutics, 2009, 30, 919-929.	1.9	26
71	A device for 24 hour ambulatory monitoring of abdominal girth using inductive plethysmography. Physiological Measurement, 2002, 23, 661-670.	1.2	25
72	Acute diarrhoea induces rectal sensitivity in women but not men Gut, 1995, 37, 270-273.	6.1	24

#	Article	IF	Citations
73	GERD-Related Cough: Pathophysiology and Diagnostic Approach. Current Gastroenterology Reports, 2011, 13, 247-256.	1.1	24
74	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 1485-1494.	0.2	24
75	Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Alimentary Pharmacology and Therapeutics, 1999, 13, 927-936.	1.9	23
76	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880559.	1.4	23
77	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	22
78	DUODENAL BULB ACIDITY AND THE NATURAL HISTORY OF DUODENAL ULCERATION. Lancet, The, 1989, 334, 61-63.	6.3	20
79	Effect of composition of gastric contents on resistance to emptying of liquids from stomach in humans. Digestive Diseases and Sciences, 1988, 33, 914-918.	1.1	17
80	Opening the doors of perception in the irritable bowel syndrome. Gut, 1997, 41, 567-568.	6.1	17
81	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. Clinical Gastroenterology and Hepatology, 2022, 20, e89-e101.	2.4	17
82	Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. Alimentary Pharmacology and Therapeutics, 2021, 54, 1179-1192.	1.9	17
83	Longitudinal followâ€up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Alimentary Pharmacology and Therapeutics, 2021, 53, 1126-1137.	1.9	17
84	Effect of food consistency on gastric emptying in man Gut, 1987, 28, 1584-1588.	6.1	16
85	Systematic review and network metaâ€analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2021, 54, 98-108.	1.9	15
86	Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism. Alimentary Pharmacology and Therapeutics, 2004, 19, 805-815.	1.9	14
87	Validation of the measurement of low concentrations of 5-hydroxytryptamine in plasma using high performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 832, 173-176.	1.2	14
88	Relationship between Fluctuations of pH and Pressure in the Human Stomach and Duodenum. Digestive Diseases, 1990, 8, 71-81.	0.8	12
89	Sensory dysfunction and the irritable bowel syndrome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, 415-427.	1.0	12
90	The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opinion on Drug Safety, 2006, 5, 313-327.	1.0	12

#	Article	IF	Citations
91	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 2010, 3, 291-305.	1.4	12
92	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Trials, 2019, 20, 517.	0.7	12
93	Effect of Intraduodenal Infusion of Acid on the Antropyloroduodenal Motor Unit in Human Volunteers. Neurogastroenterology and Motility, 1990, 2, 202-208.	1.6	11
94	Acknowledgements. Expert Review of Gastroenterology and Hepatology, 2013, 7, 289-289.	1.4	11
95	A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough. ERJ Open Research, 2022, 8, 00546-2021.	1.1	11
96	Use of hypnotherapy in gastrointestinal disorders. European Journal of Gastroenterology and Hepatology, 1996, 8, 525-529.	0.8	10
97	Esophageal dysmotility according to Chicago classification v3.0 vs v2.0: Implications for association with reflux, bolus clearance, and allograft failure postâ€lung transplantation. Neurogastroenterology and Motility, 2018, 30, e13296.	1.6	10
98	Bloating in constipation: Relevance of intraluminal gas handling. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 141-150.	1.0	9
99	The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis. American Journal of Gastroenterology, 2021, 116, 1189-1200.	0.2	8
100	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. Neurogastroenterology and Motility, 2022, 34, e14391.	1.6	8
101	Gender differences in plasma 5-hydroxytryptamine (5-HT) concentration in diarrhoea predominant irritable bowel syndrome (d-IBS): Influence of the menstrual cycle. Gastroenterology, 2003, 124, A388.	0.6	7
102	Unilateral Versus Bilateral Lung Transplantation. Journal of Clinical Gastroenterology, 2019, 53, 284-289.	1.1	7
103	Gastro-oesophageal reflux events: just another trigger in chronic cough?. Gut, 2017, 66, 2047-2048.	6.1	6
104	Heartburn as a Marker of the Success of Acid Suppression Therapy in Chronic Cough. Lung, 2021, 199, 597-602.	1.4	6
105	Neural and Hormonal Control of Pyloric Sphincter Function. Scandinavian Journal of Gastroenterology, 1989, 24, 27-31.	0.6	5
106	Irritable Bowel Syndrome in Middle-Aged and Elderly Palestinians: Its Prevalence and Effect of Location of Residence. American Journal of Gastroenterology, 2014, 109, 723-739.	0.2	5
107	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. Journal of Cellular and Molecular Medicine, 2021, 25, 8047-8061.	1.6	5
108	Editorial: Breaking the Sound Barrier? Pitfalls and Benefits of Acoustic Cough Monitoring. American Journal of Gastroenterology, 2012, 107, 1833-1836.	0.2	4

#	Article	IF	Citations
109	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. Neurogastroenterology and Motility, 2022, 34, e14268.	1.6	4
110	Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and ph, and orocecal and colonic transit: Two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers. Clinical Therapeutics, 2006, 28, 569-581.	1.1	3
111	No association between the common calcium-sensing receptor polymorphism rs1801725 and irritable bowel syndrome. BMC Medical Genetics, 2015, 16, 110.	2.1	3
112	O61â€Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. , 2021, , .		2
113	Abdominal distension in pre- and post-menopausal females with irritable bowel syndrome (IBS): The effect of the contraceptive pill and hormone replacement therapy. Gastroenterology, 2000, 118, A140.	0.6	1
114	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoeaâ€"are we any closer?. Alimentary Pharmacology and Therapeutics, 2019, 50, 825-826.	1.9	1
115	Gas and Bloating. , 2015, , 113-123.		1
116	Gastro-oesophageal reflux and cough. Journal of the Association of Physicians of India, The, 2013, 61, 17-9.	0.0	1
117	Evaluation of Anorectal Function in Perianal Crohn's Disease: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 5909.	1.0	1
118	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, vii.	1.0	0
119	PWE-076â€Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
120	O63â€Gastrointestinal symptom-specific anxiety and symptom severity in irritable bowel syndrome: new insights from factor analysis. , 2021, , .		0
121	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloatingâ€"a step in the right direction for targeted treatment? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 198-199.	1.9	O
122	P326 Identification of novel subgroups in irritable bowel syndrome using latent class analysis: beyond stool form. , 2021, , .		0
123	Editorial: understanding IBS pathophysiology through "converging channels―of research—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1215-1216.	1.9	0